Review





Similar Products

ctc  (RareCyte Inc)
90
RareCyte Inc ctc
Ctc, supplied by RareCyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctc/product/RareCyte Inc
Average 90 stars, based on 1 article reviews
ctc - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
primer smo l l mutant reverse ctc cag act gcc ttg gga aaa  (Jackson Laboratory)
86
Jackson Laboratory primer smo l l mutant reverse ctc cag act gcc ttg gga aaa
Primer Smo L L Mutant Reverse Ctc Cag Act Gcc Ttg Gga Aaa, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primer smo l l mutant reverse ctc cag act gcc ttg gga aaa/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
primer smo l l mutant reverse ctc cag act gcc ttg gga aaa - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
primer smo l l common forward gga ctc gca gga gga agc  (Jackson Laboratory)
86
Jackson Laboratory primer smo l l common forward gga ctc gca gga gga agc
Primer Smo L L Common Forward Gga Ctc Gca Gga Gga Agc, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primer smo l l common forward gga ctc gca gga gga agc/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
primer smo l l common forward gga ctc gca gga gga agc - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
ctc resin  (Iris Biotech Gmbh)
86
Iris Biotech Gmbh ctc resin
Ctc Resin, supplied by Iris Biotech Gmbh, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctc resin/product/Iris Biotech Gmbh
Average 86 stars, based on 1 article reviews
ctc resin - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
ctcs  (Menarini Silicon Biosystems)
86
Menarini Silicon Biosystems ctcs
Clinical characteristics and CTC detection in patients with mBC. A Summary of the patients’ characteristics. Their mean age was 61.55 years (± 13.36) and most patients had HR + /HER2 − (83.3%, n = 50), followed by HR + /HER2 + (8.3%, n = 5), HR − /HER2 + (5.0%, n = 3), and triple-negative HR − /HER2 − cancer (3.3%, n = 2). First-line treatments included hormone therapy combined with CDK4/6 inhibitors, hormone therapy alone, chemotherapy alone, chemotherapy combined with targeted therapy, chemotherapy combined with immunotherapy, and other regimens. B Sankey diagram (left) showing the distribution of metastatic sites in the study cohort. The most frequent sites were bone, liver, lymph nodes and lung, followed by pleura, peritoneum, brain, pancreas, adrenal gland, skin and duodenum. Each line represents an individual patient. Histogram (right) showing the number of metastatic sites per patient. Most patients had one ( n = 26) or two ( n = 23) metastatic sites. C Schematic representation of CTC analysis in the 60 patients with mBC using <t>the</t> <t>CellSearch</t> ® platform: 35 were classified as CTC-positive (≥ 5 <t>CTCs/7.5</t> mL of blood), and 25 as CTC-negative. Representative images of CTCs identified by CellSearch ® . CTCs were defined as EpCAM + (based on the enrichment step), nucleated (DAPI⁺), cytokeratin-positive (CK⁺/FITC), and CD45⁻ (exclusion marker, APC) cells. Images show merged and individual fluorescence channels for both CTC-positive and CTC-negative samples
Ctcs, supplied by Menarini Silicon Biosystems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctcs/product/Menarini Silicon Biosystems
Average 86 stars, based on 1 article reviews
ctcs - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
ctc count  (Menarini Silicon Biosystems)
86
Menarini Silicon Biosystems ctc count
<t>CTC</t> <t>count</t> related to PFS and OS. CTC count < 5: blue line; CTC count ≥ 5: red line. ( A ) PFS in patients with positive ER expression by IHC; ( B ) OS in patients with positive ER expression by IHC. ( C ) PFS in patients with FES-PET positive result; ( D ) OS in patients with FES-PET positive result.
Ctc Count, supplied by Menarini Silicon Biosystems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctc count/product/Menarini Silicon Biosystems
Average 86 stars, based on 1 article reviews
ctc count - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
tissue culture ctc service  (Boehringer Ingelheim)
86
Boehringer Ingelheim tissue culture ctc service
<t>CTC</t> <t>count</t> related to PFS and OS. CTC count < 5: blue line; CTC count ≥ 5: red line. ( A ) PFS in patients with positive ER expression by IHC; ( B ) OS in patients with positive ER expression by IHC. ( C ) PFS in patients with FES-PET positive result; ( D ) OS in patients with FES-PET positive result.
Tissue Culture Ctc Service, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tissue culture ctc service/product/Boehringer Ingelheim
Average 86 stars, based on 1 article reviews
tissue culture ctc service - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Clinical characteristics and CTC detection in patients with mBC. A Summary of the patients’ characteristics. Their mean age was 61.55 years (± 13.36) and most patients had HR + /HER2 − (83.3%, n = 50), followed by HR + /HER2 + (8.3%, n = 5), HR − /HER2 + (5.0%, n = 3), and triple-negative HR − /HER2 − cancer (3.3%, n = 2). First-line treatments included hormone therapy combined with CDK4/6 inhibitors, hormone therapy alone, chemotherapy alone, chemotherapy combined with targeted therapy, chemotherapy combined with immunotherapy, and other regimens. B Sankey diagram (left) showing the distribution of metastatic sites in the study cohort. The most frequent sites were bone, liver, lymph nodes and lung, followed by pleura, peritoneum, brain, pancreas, adrenal gland, skin and duodenum. Each line represents an individual patient. Histogram (right) showing the number of metastatic sites per patient. Most patients had one ( n = 26) or two ( n = 23) metastatic sites. C Schematic representation of CTC analysis in the 60 patients with mBC using the CellSearch ® platform: 35 were classified as CTC-positive (≥ 5 CTCs/7.5 mL of blood), and 25 as CTC-negative. Representative images of CTCs identified by CellSearch ® . CTCs were defined as EpCAM + (based on the enrichment step), nucleated (DAPI⁺), cytokeratin-positive (CK⁺/FITC), and CD45⁻ (exclusion marker, APC) cells. Images show merged and individual fluorescence channels for both CTC-positive and CTC-negative samples

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer

doi: 10.1186/s13046-026-03709-3

Figure Lengend Snippet: Clinical characteristics and CTC detection in patients with mBC. A Summary of the patients’ characteristics. Their mean age was 61.55 years (± 13.36) and most patients had HR + /HER2 − (83.3%, n = 50), followed by HR + /HER2 + (8.3%, n = 5), HR − /HER2 + (5.0%, n = 3), and triple-negative HR − /HER2 − cancer (3.3%, n = 2). First-line treatments included hormone therapy combined with CDK4/6 inhibitors, hormone therapy alone, chemotherapy alone, chemotherapy combined with targeted therapy, chemotherapy combined with immunotherapy, and other regimens. B Sankey diagram (left) showing the distribution of metastatic sites in the study cohort. The most frequent sites were bone, liver, lymph nodes and lung, followed by pleura, peritoneum, brain, pancreas, adrenal gland, skin and duodenum. Each line represents an individual patient. Histogram (right) showing the number of metastatic sites per patient. Most patients had one ( n = 26) or two ( n = 23) metastatic sites. C Schematic representation of CTC analysis in the 60 patients with mBC using the CellSearch ® platform: 35 were classified as CTC-positive (≥ 5 CTCs/7.5 mL of blood), and 25 as CTC-negative. Representative images of CTCs identified by CellSearch ® . CTCs were defined as EpCAM + (based on the enrichment step), nucleated (DAPI⁺), cytokeratin-positive (CK⁺/FITC), and CD45⁻ (exclusion marker, APC) cells. Images show merged and individual fluorescence channels for both CTC-positive and CTC-negative samples

Article Snippet: CTCs were identified using the FDA-cleared CellSearch ® system (Menarini Silicon Biosystems, Inc., Bologna, Italy).

Techniques: Marker, Fluorescence

CTC count related to PFS and OS. CTC count < 5: blue line; CTC count ≥ 5: red line. ( A ) PFS in patients with positive ER expression by IHC; ( B ) OS in patients with positive ER expression by IHC. ( C ) PFS in patients with FES-PET positive result; ( D ) OS in patients with FES-PET positive result.

Journal: Diagnostics

Article Title: Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer

doi: 10.3390/diagnostics16081197

Figure Lengend Snippet: CTC count related to PFS and OS. CTC count < 5: blue line; CTC count ≥ 5: red line. ( A ) PFS in patients with positive ER expression by IHC; ( B ) OS in patients with positive ER expression by IHC. ( C ) PFS in patients with FES-PET positive result; ( D ) OS in patients with FES-PET positive result.

Article Snippet: CTC count was measured in 7.5 mL of CellSave blood within 96 h after collection, using the CellSearch System (Menarini-Silicon Biosystems).

Techniques: Expressing